AcuCort (”AcuCort” eller ”Bolaget”) meddelade den 13 november år 2024 att samtliga patienter har gen...
Irisity AB (”Irisity” or ”the Company”) is a leading provider of AI-driven video analytics solutions...
Q3 in line with pre-announcement Strong Q4 on the cards; 20% sales growth q-o-q No change to FY guid...
Nu är guldproduktionen i Fäbodtjärn i gång. Gruvan invigdes i maj och i augusti sköts den första mal...
Redeye sees a Q3 report from BrightBid on the soft side regarding ARR growth.
Redeye comments on yesterday’s news that Kancera will concentrate its resources on cardiovascular di...
Redeye saw a Q3 report in which sales and gross margins slightly exceeded our estimates.
Redeye views the Q3 report as relatively uneventful, apart from the apparent successful launch of Te...
Higher sales and gross margin in Q3 EBIT revised up 12.
Q3 in line with promising outlook for 2025 Large revisions as Kaktus divestment moving from '24e to ...
Trots att försäljning och resultat kom in under våra förväntningar i kvartalet kvarstår vår positiva...
Redeye saw a Q3 report showing sales above our estimates, with a total growth of 16% for the quarter...
Redeye shares its initial take on Physitrack’s Q3 results, which were generally in line with our mod...
Redeye gives a short comment on yesterday’s news that Curasight has announced brain cancer as the fi...
Redeye sees a solid Q3 report with an improved cash burn, and we welcome the increased gross margin ...
Redeye comments in EG7’s Q3-results which were better than expected, driven by strong profitability ...
Redeye provides an updated view on Nanologica following the company’s Q3 report.
In its CMD, Vaisala outlined its strategy and updated long-term financial targets.
Redeye reiterates its valuation following the Q3 2024 report, which showed slight positive deviation...
Redeye comments on Optomed’s increased full-year outlook and changes our Q4 2024 sales estimate acco...